Therapeutic Response and Antifungal Susceptibility to Fluconazole in Women with Vulvovaginal Candidiasis
Background and Aim: Vulvovaginal candidiasis (VVC) is a vaginal fungal infection that mainly caused by Candida albicans. Among various treatments and their controversial outcomes, oral fluconazole has been accepted as a common and efficient treatment for acute and chronic cases. The aim of this stud...
Saved in:
Main Authors: | Zahra Vahedpoor (Author), Mohammad Javad Azadchehr (Author), Taha Baghbani (Author), Tayebeh Felfelian Fini (Author), Mehdi Nazeri (Author) |
---|---|
Format: | Book |
Published: |
Tehran University of Medical Sciences,
2022-04-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Vaginal and oral use of probiotics as adjunctive therapy to fluconazole in patients with vulvovaginal candidiasis: A clinical trial on Iranian women
by: Zahra Vahedpoor, et al.
Published: (2021) -
Vulvovaginal candidiasis: species distribution of Candida and their antifungal susceptibility pattern
by: Adane Bitew, et al.
Published: (2018) -
Use of antifungals in the treatment of vulvovaginal candidiasis: an integrative review
by: Kellyane Folha Gois Moreira, et al.
Published: (2023) -
Combination of antifungal agent and prebiotic for acute vulvovaginal candidiasis
by: Krotin P.N, et al.
Published: (2019) -
Characterization of Candida species isolated from vulvovaginal candidiasis by MALDI-TOF with in vitro antifungal susceptibility profiles
by: Narges Aslani, et al.
Published: (2021)